Multifocal Motor Neuropathy (MMN)

How MMN affects the nerves

MMN is one of the immune-mediated forms of peripheral neuropathy. In MMN, the immune system attacks motor nerves at specific points along their length, often where antibodies target a nerve component called GM1 ganglioside. This disrupts signal conduction (conduction block), so the muscles supplied by that nerve weaken even though the nerve and muscle are otherwise intact. Sensory nerves are spared, which is why there is no numbness. Over years, if untreated, the nerve fibers themselves (axons) can be lost, causing muscle wasting.

Symptoms

• weakness in the distribution of individual nerves, usually in the arms first: weak grip, finger drop, wrist drop (mimicking a radial nerve injury), difficulty with buttons or keys
• asymmetric: one hand or arm is often much weaker than the other
• muscle twitching (fasciculations) and cramps
• muscle wasting in long-standing disease
• worsening in cold
• legs affected in some people, causing foot drop
• normal sensation, or only very minor sensory symptoms
• reduced reflexes in affected limbs
• no pain

Symptoms usually progress slowly over months to years, sometimes in steps.

MMN vs ALS and other conditions

Because MMN is treatable and ALS is not, careful nerve testing is crucial for anyone with lower motor neuron weakness.

Causes

MMN is autoimmune. About half of patients have IgM antibodies against GM1 ganglioside, which bind to nodes along motor nerves and activate complement, damaging the nerve. What triggers the immune response is unknown, and it is not inherited.

Diagnosis

• Neurological examination: mapping which muscles and nerves are weak, confirming normal sensation.
• Nerve conduction studies: the key test, showing motor conduction block outside common compression sites, with normal sensory responses across the same segments.
• Anti-GM1 antibody blood test: positive in around 40 to 50%. A negative result does not exclude MMN.
• Nerve ultrasound or MRI of the brachial plexus: may show swollen nerves.
• Spinal fluid: usually normal or only mildly raised protein.
• Response to IVIG: a clear improvement supports the diagnosis.

The EFNS/PNS guideline provides criteria for definite and probable MMN.

Treatment

• Immunoglobulin (IVIG): the first-line and best-established treatment. Most patients improve within days to weeks of an infusion. Effects wear off, so maintenance infusions every 2 to 6 weeks are typically needed, adjusted to the lowest effective dose.
• Subcutaneous immunoglobulin (SCIG): given at home, an alternative for maintenance in many patients.
• Other options for people who respond incompletely: cyclophosphamide or rituximab have been tried, with limited evidence. Complement inhibitors are being studied.
• Avoid steroids and plasma exchange, which do not help and may worsen weakness.
• Supportive care: occupational therapy, hand splints, wrist and ankle braces, and adaptive tools.

Outlook

MMN progresses slowly and does not usually shorten life. With immunoglobulin, most people stabilize or improve, especially when treatment begins before significant axon loss and muscle wasting. Some weakness can persist despite treatment, and many people need long-term maintenance therapy.

Frequently asked questions

What is multifocal motor neuropathy?

MMN is a rare autoimmune disease affecting motor nerves. It causes slowly worsening, painless weakness in a patchy pattern, usually in the hands and arms, without numbness. It is caused by immune attack at specific points along the nerves.

How is MMN different from ALS?

MMN affects individual peripheral motor nerves, shows conduction block on nerve testing and responds well to immunoglobulin. ALS affects motor neurons in the brain and spinal cord, often involves speech and swallowing, and does not respond to immune treatment.

What are the first symptoms of MMN?

Early symptoms often include weakness in one hand, such as difficulty gripping, extending fingers or using keys, plus muscle cramps and twitching. Sensation remains normal. Symptoms may be worse in cold weather.

How is multifocal motor neuropathy treated?

The main treatment is immunoglobulin, given intravenously (IVIG) or under the skin (SCIG) at regular intervals. Most people improve or stabilize. Steroids and plasma exchange are not effective and can make MMN worse.

Is multifocal motor neuropathy curable?

MMN is not usually cured, but it is very treatable. Most people need ongoing immunoglobulin to maintain strength. Starting treatment early, before nerve fibers are lost, gives the best long-term results.